Imfinzi/treme­li­mum­ab com­bo scores As­traZeneca an­oth­er OS win — this time in liv­er can­cer

Is the tide turn­ing on As­traZeneca’s bat­tered PD-L1/CT­LA4 com­bo?

A sin­gle prim­ing dose of the ex­per­i­men­tal treme­li­mum­ab, fol­lowed by Imfinzi every four weeks, beat Nex­avar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER